Topic
Obesity medicine
2 reports, newest first.
Chemically synthesised semaglutide HD1916 met equivalence with Wegovy for weight loss in Chinese adults
A 44-week open-label phase III trial in 462 Chinese adults with obesity found HD1916 equivalent to reference semaglutide for body weight reduction, with similar adverse events.
Triple agonist UBT251 lowered body weight over 24 weeks in a phase 2 trial
In a 24-week phase 2 trial of 205 adults with overweight or obesity and without type 2 diabetes, once-weekly UBT251 reduced body weight more than placebo.
Today's Rounds, in your inbox at 8am
The day's reports each morning, and Weekend Rounds on Saturday. Free, no advertising.